Structure Therapeutics Inc. - American Depositary Shares (GPCR)
30.70
+0.75 (2.50%)
Structure Therapeutics Inc. is a biotechnology company that focuses on the discovery and development of innovative therapies targeting G protein-coupled receptors (GPCRs), which are essential in mediating various physiological processes and diseases
By leveraging advanced structural biology and computational techniques, the company aims to design small molecule treatments for a range of conditions, including metabolic disorders and neurodegenerative diseases. Through its research efforts, Structure Therapeutics strives to create effective and targeted therapeutics that can improve patient outcomes and contribute to advancements in personalized medicine.
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.
Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest clinical trial data.
